- Home
- WLGS vs LPCN Comparison
WLGS vs LPCN Comparison
Compare WLGS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- LPCN
- Stock Information
- Founded
- WLGS 1981
- LPCN 1997
- Country
- WLGS Hong Kong
- LPCN United States
- Employees
- WLGS N/A
- LPCN N/A
- Industry
- WLGS Engineering & Construction
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- LPCN Health Care
- Exchange
- WLGS Nasdaq
- LPCN Nasdaq
- Market Cap
- WLGS 41.7M
- LPCN 36.8M
- IPO Year
- WLGS 2023
- LPCN N/A
- Fundamental
- Price
- WLGS $2.29
- LPCN $5.03
- Analyst Decision
- WLGS
- LPCN Strong Buy
- Analyst Count
- WLGS 0
- LPCN 1
- Target Price
- WLGS N/A
- LPCN $10.00
- AVG Volume (30 Days)
- WLGS 127.2K
- LPCN 28.2K
- Earning Date
- WLGS 12-24-2024
- LPCN 11-07-2024
- Dividend Yield
- WLGS N/A
- LPCN N/A
- EPS Growth
- WLGS N/A
- LPCN N/A
- EPS
- WLGS N/A
- LPCN N/A
- Revenue
- WLGS $6,825,879.00
- LPCN $7,922,926.00
- Revenue This Year
- WLGS N/A
- LPCN N/A
- Revenue Next Year
- WLGS N/A
- LPCN N/A
- P/E Ratio
- WLGS N/A
- LPCN N/A
- Revenue Growth
- WLGS 63.69
- LPCN N/A
- 52 Week Low
- WLGS $0.44
- LPCN $2.44
- 52 Week High
- WLGS $5.57
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- WLGS 38.98
- LPCN 50.88
- Support Level
- WLGS $2.31
- LPCN $4.70
- Resistance Level
- WLGS $3.19
- LPCN $5.28
- Average True Range (ATR)
- WLGS 0.65
- LPCN 0.32
- MACD
- WLGS -0.23
- LPCN 0.04
- Stochastic Oscillator
- WLGS 2.96
- LPCN 69.53
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.